|
2024
|
G/S
|
Pharmaceutical preparations for human use. Pharmaceutical research and development services; phar... |
|
|
Invention
|
Deuterated tryptamine derivatives and methods of use.
The present disclosure is directed to chem... |
|
|
Invention
|
Therapeutic phenethylamine compositions and methods of use.
There are disclosed deuterated 2C—X ... |
|
|
Invention
|
Companion animal treatments. 22 receptor, such as anxiety disorders (e.g., separation anxiety, so... |
|
|
Invention
|
Injectable pharmaceutical formulations. 22 receptor. |
|
|
Invention
|
Methods of treating depressive disorders with a psilocybin analog. The present disclosure relates... |
|
|
Invention
|
Methods of treating disorders with a psilocybin analog.
The present disclosure relates generally... |
|
2023
|
Invention
|
Phenethylamine compounds, compositions, and methods of use. 222 receptor. |
|
|
Invention
|
Deuterated tryptamine derivatives and methods of use. 2 receptor. |
|
|
Invention
|
Tryptamine compounds, compositions, and methods of use. 222 receptor. |
|
|
Invention
|
Deuterated tryptamine derivatives and methods of use. 2 receptor.
|
|
|
Invention
|
Solid dispersions of psilocybin. 2 2 receptor. The pharmaceutical compositions are formulated wit... |
|
|
Invention
|
Combination of nitrous oxide and 5-ht2a receptor agonists. 2ANviavia aerosol inhalation. |
|
|
Invention
|
Phenethylamine derivatives, compositions, and methods of use. There are disclosed psychedelic and... |
|
|
Invention
|
Therapeutic phenethylamine compositions and methods of use. 222 receptor, such as central nervous... |
|
|
Invention
|
Tryptamine compositions and methods.
There are disclosed pharmaceutically acceptable salts of tr... |
|
|
Invention
|
Tryptamine compositions and methods. 222 receptor, such as central nervous system (CNS) disorders... |
|
2022
|
Invention
|
Deuyerated tryptamine derivative formulations and methods of use.
The present disclosure is dire... |
|
|
Invention
|
Formulations of psilocybin analogs and methods of use. The present disclosure relates to pharmace... |
|
|
Invention
|
Formulations of psilocybin analogs and methods of use. 22 receptor, are also disclosed. |
|
|
Invention
|
Integrated data collection devices for use in various therapeutic and wellness applications.
Sys... |
|
|
Invention
|
Integrated data collection devices for use in various therapeutic and wellness applications. Syst... |
|
|
Invention
|
Formulations of psilocybin.
The present disclosure relates to stable pharmaceutical compositions... |
|
|
Invention
|
Formulations of psilocybin. 22 receptor. The pharmaceutical compositions are formulated with soli... |
|
|
Invention
|
Formulations of psilocybin. The present disclosure relates to stable pharmaceutical compositions ... |
|
|
Invention
|
Combination drug therapies.
Combination drag therapies comprising a 5-HTZA receptor agonist and ... |
|
|
Invention
|
Combination drug therapies. Combination drag therapies comprising a 5-HTZA receptor agonist and a... |
|
|
Invention
|
Combination drug therapies. NN-methyl-D-aspartate (NMDA) receptor antagonist (e.g., nitrous oxide... |
|
|
Invention
|
Psilocybin analogs, salts, compositions, and methods of use.
The present disclosure relates to p... |
|
|
Invention
|
Psilocybin analogs, salts, compositions, and methods of use. 222 receptor. |
|
|
Invention
|
Psilocybin analogs, salts, compositions, and methods of use. The present disclosure relates to ps... |
|
2021
|
Invention
|
Methods for delivery of psychedelic medications by inhalation and systems for performing the meth... |
|
|
Invention
|
Phenethylamine derivatives, compositions, and methods of use.
There are disclosed psychedelic an... |
|
|
Invention
|
Therapeutic phenethylamine compositions and methods of use. 2 receptor, such as central nervous s... |
|
|
Invention
|
Phenethylamine derivatives, compositions, and methods of use. 222 receptor, such as central nervo... |
|
|
Invention
|
Therapeutic phenethylamine compositions and methods of use. There are disclosed deuterated 2C-X p... |
|
|
Invention
|
Deuterated tryptamine derivatives and methods of use. The present disclosure is directed to chemi... |
|
|
Invention
|
Deuterated tryptamine derivatives and methods of use. 22 receptor. |
